{
    "clinical_study": {
        "@rank": "63598", 
        "arm_group": [
            {
                "arm_group_label": "AS902330 (100 mcg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AS902330 (30 mcg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2, double-blind, multicenter, randomized, placebo-controlled trial to\n      evaluate the efficacy and safety of AS902330 (recombinant human fibroblast growth factor-18\n      [rhFGF-18]) as an adjunct treatment to subjects following microfracture (MFx) surgery for\n      cartilage injury of the knee.\n\n      Primary Objectives\n\n        -  To evaluate the effect of AS902330 intra-articular knee injections as adjunct to MFx\n           surgery on the composition of the refilled cartilage in the target knee, as measured by\n           gadolinium-enhanced Magnetic Resonance Imaging (MRI) of cartilage (dGEMRIC) T1\n           relaxation time at 6 months after MFx surgery\n\n        -  To evaluate the safety profile of AS902330 when administered intra-articular into the\n           knee as adjunct to MFx surgery in subjects with cartilage injury of the knee\n\n      Secondary Objectives\n\n        -  To further support the efficacy and safety of AS902330 as an adjunct to MFx  for\n           cartilage  injury  repair  through  symptomatic  outcomes  and  quantitative  MRI\n           measurement"
        }, 
        "brief_title": "A Multicenter Trial of AS902330 (Recombinant Human Fibroblast Growth Factor-18) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cartilage Repair of Knee", 
            "Microfracture Surgery of Knee"
        ], 
        "condition_browse": {
            "mesh_term": "Wounds and Injuries"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects with candidature for MFx on the femoral articular surfaces (medial or\n             lateral condyles or trochlear groove), with intact subchondral bone\n\n          2. Subjects with moderate to severe pain in the target knee prior to surgery; average\n             score greater than equal to (>=) 4.0 over 7 consecutive days on Numeric Rating Scale\n             of Pain Intensity (completed within 30 [+15] days before surgery)\n\n          3. Intraoperative inclusion criteria: Subjects with 1 or 2 focal chondral lesions per\n             target knee, where peripheral debridement to healthy cartilage results in all of the\n             following:\n\n               -  Each lesion has an area of >= 1 centimeter square (cm^2) and less than equal to\n                  (<=) 4 cm^2\n\n               -  Each lesion is <= 6 millimeter (mm) in depth, as measured from the surrounding\n                  subchondral plate\n\n               -  Arthroscopic confirmation that each non-osteochondritis dissecans (OCD) lesion\n                  is between International Cartilage Repair Society (ICRS) Grades I and III (D); a\n                  Grade III non-OCD lesion is equivalent to an Outerbridge Grade IV lesion with\n                  minimal subchondral bone loss\n\n        Additional Inclusion Criteria apply\n\n        Exclusion Criteria:\n\n          1. Subjects with prior marrow stimulation treatment of the target knee, that is, MFx,\n             micro-drilling, abrasion chondroplasty or cartilage repair including, but not limited\n             to, autologous chondrocyte implantation (ACI), matrix/membrane autologous chondrocyte\n             implantation (MACI), or osteochondral transplantation (autologous or allogeneic)\n\n          2. Subjects with Body Mass Index (BMI) of greater than 35 kilogram per meter square\n             (kg/m^2) at screening\n\n          3. Malalignment of the target knee greater than 5 degrees as measured from the\n             mechanical axis, as confirmed by alignment (long bone) X-ray images\n\n          4. Subjects with clinical and/or radiographic disease diagnosis of the target knee joint\n             including, but not limited to, the following: generalized osteoarthritis (OA),\n             rheumatoid arthritis, or avascular necrosis\n\n          5. Subjects who have any contraindication to MRI or gadolinium-based or iodinated\n             contrast agents according to the site's standard practice guidelines\n\n        Additional Exclusion Criteria apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689337", 
            "org_study_id": "EMR700692_007", 
            "secondary_id": "2012-001431-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "AS902330 (30 mcg)", 
                "description": "AS902330, 30 mcg will be administered as  intra-articular  injection once weekly for 3 weeks, starting from 2 weeks after MFx surgery", 
                "intervention_name": "AS902330 (30 microgram [mcg] )", 
                "intervention_type": "Drug", 
                "other_name": "rhFGF-18"
            }, 
            {
                "arm_group_label": "AS902330 (100 mcg)", 
                "description": "AS902330, 100 mcg will be administered as  intra-articular  injection once weekly for 3 weeks, starting from 2 weeks after MFx surgery", 
                "intervention_name": "AS902330 (100 microgram [mcg])", 
                "intervention_type": "Drug", 
                "other_name": "rhFGF-18"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo matched to either  AS902330, 30 mcg or 100 mcg will be administered as intra-articular injection once weekly for 3 weeks, starting from 2 weeks after MFx surgery", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "microfracture surgery, cartilage repair, knee surgery", 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boise", 
                    "country": "United States", 
                    "state": "Idaho"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 Mcg and 100 Mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composition of the refilled cartilage measured by delayed gadolinium-enhanced Magnetic Resonance Imaging (MRI) of cartilage (dGEMRIC) T1 relaxation time at Month 6 post-MFx surgery", 
            "safety_issue": "No", 
            "time_frame": "Month 6"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689337"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Composition of the refilled cartilage measured by delayed gadolinium-enhanced Magnetic Resonance Imaging (MRI) of cartilage (dGEMRIC) T1 relaxation time", 
                "safety_issue": "No", 
                "time_frame": "after Month 6, every 6 months up to 5 years"
            }, 
            {
                "measure": "Change from Baseline in patient reported outcome measure: Knee Injury and Osteoarthritis Outcome Score (KOOS) sub-scores for pain and activities of daily living (ADL)", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Change from Baseline in patient reported outcome measure: Total KOOS score, KOOS sub-scores dimensions and Total KOOS minus Function in Sports and Recreational Activities (FSR) sub score", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Change from Baseline in patient reported outcome measure: Numeric Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Change from Baseline in patient reported outcome measure: Lower Extremity Activity Scale (LEAS)", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Change from Baseline in the physician-reported outcome measure: Lysholm Knee Scale score", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Composition of the refilled cartilage as evaluated through T2 mapping", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Volume of the refilled cartilage", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 5 years"
            }, 
            {
                "measure": "Six-minute walk test", 
                "safety_issue": "No", 
                "time_frame": "starting at Month 6 - every 3 months up to 5 years"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}